Stocks Health care IPSC
NASDAQ · Health careCentury Therapeutics, Inc. (IPSC)
It posted a net loss of $109.8M. In fiscal 2025 capital spending exceeded operating cash flow by $104.7M. At June 30, 2026 it held $49.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Century Therapeutics, Inc.
- Net worth
- Century Therapeutics, Inc. has a market value (market cap) of $327.7M at the latest share price, and shareholders' equity of $232.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $109.2M (+1,556.8% year on year), with a net loss of $9.6M.
- Cash flow
- In fiscal 2025 operations used $103.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Century Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Century Therapeutics, Inc. does
Century Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker IPSC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $109.2M | -$9.6M | -$0.14 | -$104.7M |
| 2024 | $6.6M | -$126.6M | -$1.61 | -$110.3M |
| 2023 | $2.2M | -$136.7M | -$2.30 | -$102.1M |
| 2022 | $5.2M | -$130.9M | -$2.96 | -$16.6M |
| 2021 | n/a | -$95.8M | -$3.86 | -$134M |
| 2021 | n/a | -$53.6M | -$9.34 | -$51.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IPSC ranks in Health care
Latest SEC filings
What Century Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 2, 2026
- September 9, 2026
- August 12, 2026
- August 12, 2026
- June 16, 2026
- June 12, 2026
- June 8, 2026Other event 8-K
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 13, 2026
Insider trades
What the people running Century Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $10.2K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Carr DouglasSVP Finance & Operations | Sold | 266 | $404.1 |
| September 14, 2026 | Carr DouglasSVP Finance & Operations | Sold | 1,658 | $3.2K |
| September 14, 2026 | Russotti GregorySee Remarks | Sold | 2,587 | $5K |
| September 11, 2026 | Pfeiffenberger BrentPresident and CEO, Director | Shares withheld for tax | 13,850 | $26.9K |
| September 8, 2026 | Carr DouglasSVP Finance & Operations | Sold | 254 | $520.7 |
| September 8, 2026 | Russotti GregorySee Remarks | Sold | 534 | $1.1K |
| September 4, 2026 | Pfeiffenberger BrentPresident and CEO, Director | Shares withheld for tax | 463 | $976.9 |
| August 14, 2026 | Pfeiffenberger BrentPresident and CEO, Director | Shares withheld for tax | 31,172 | $59.9K |
Who owns IPSC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Chen Yu13G, passive with 4 related filers | 9.9% | January 15, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | January 16, 2026 |
| Deep Track Capital, LP13G, passive with 3 related filers | 7.34% | January 15, 2026 |
| Commodore Capital LP13G, passive with 3 related filers | 7.1% | January 16, 2026 |
| RTW Investments, LP13G, passive with 1 related filers | 7.1% | May 15, 2026 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 7.1% | January 16, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 99 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 17,754,430 | 0 |
| TCG Crossover Management, LLC | 17,754,430 | 0 |
| Versant Venture Management, LLC | 12,166,109 | 0 |
| Deep Track Capital, LP | 9,462,645 | -25,100 |
| Rtw Investments, LP | 8,695,652 | 0 |
| Venrock Adviser, LLC | 8,695,652 | 0 |
| Commodore Capital LP | 8,695,652 | 0 |
| BlackRock, Inc. | 8,091,768 | +6,567,346 |
| Vanguard Capital Management LLC | 5,703,680 | +17,476 |
| Balyasny Asset Management L.P. | 5,522,944 | +505,211 |
| Point72 Asset Management, L.P. | 4,980,526 | -984,152 |
| Seven Fleet Capital Management LP | 4,347,826 | +1,400,000 |
| Woodline Partners LP | 4,257,530 | +1,214,052 |
| Millennium Management LLC | 4,194,981 | -472,082 |
| Trails Edge Capital Partners, LP | 4,134,969 | +1,684,976 |
| Spruce Street Capital LP | 4,059,054 | 0 |
| Adage Capital Partners GP, L.L.C. | 3,789,538 | 0 |
| Geode Capital Management, LLC | 2,979,529 | +1,677,865 |
| Two Sigma Investments, LP | 2,699,013 | +327,583 |
| DAFNA Capital Management LLC | 2,400,458 | -33,895 |
Insiders
4 insiders reported holding 5,821,000 shares in total, about $10.5M at the last price.
| Holder | Shares |
|---|---|
| Pfeiffenberger BrentPresident and CEO, Director | 3,633,839 |
| Cowan ChadChief Scientific Officer | 1,175,322 |
| Russotti GregorySee Remarks | 509,198 |
| Carr DouglasSVP Finance & Operations | 502,641 |
Questions about IPSC
What does Century Therapeutics, Inc. do?
Century Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as IPSC. Its shares trade on NASDAQ under the ticker IPSC.
What is Century Therapeutics, Inc.'s net worth?
Century Therapeutics, Inc. has a market value (market cap) of $327.7M at the latest share price, and shareholders' equity of $232.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Century Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $109.8M.
When did Century Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from November 5, 2026.
When is Century Therapeutics, Inc.'s next earnings report?
Century Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IPSC with
Follow IPSC
Get an email when Century Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Century Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.